Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | UBE2N | P61088 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 7/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798902 | 0.90 | KDM4E (0.64) | KDM4EUBE2NALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL28301827 | 0.87 | KDM4E (0.74) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL2134749 | 0.85 | KDM4E (0.67) | KDM4EUBE2NALDH1A1CA2CA9 | |
| SCHEMBL15598333 | 0.84 | ALDH1A1 (0.47) | KDM4EUBE2NALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL18080756 | 0.82 | KDM4E (0.67) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL30542068 | 0.81 | KDM4E (0.73) | KDM4EUBE2NALDH1A1CA2CA9 | |
| SCHEMBL6625206 | 0.81 | KDM4E (0.65) | KDM4EUBE2NALDH1A1CA2CA9 | |
| SCHEMBL14735377 | 0.81 | KDM4E (0.73) | KDM4EUBE2NALDH1A1CA2CA9 | |
| SCHEMBL6798197 | 0.79 | ALDH1A1 (0.41) | KDM4EUBE2NALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL6798200 | 0.79 | ALDH1A1 (0.41) | KDM4EUBE2NALDH1A1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6822100-B2 | REACTING N-SULFONYL-3-VINYLINDOLE WITH RUTHENIUM COMPLEX IN PRESENCE OF ETHYL DIAZOACETATE AND TOLUENE; PSYCHOLOGICAL, SEXUAL, AND EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-23 | — | — | US | disclosed |
| US-6777437-B2 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS. SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | MATTSON RONALD J (US) | 2004-07-22 | — | — | US | disclosed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR1A, HTR1D, TPH1 | KDM4E 3636/4885UBE2N 4027/4885ALDH1A1 516/4885 |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR5A, HTR1A, HTR2C | KDM4E 2977/4885UBE2N 3903/4885ALDH1A1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.